-DOCSTART- -X- O
This -X- _ O
study -X- _ O
was -X- _ O
designed -X- _ O
to -X- _ O
determine -X- _ O
the -X- _ O
therapeutic -X- _ O
efficacy -X- _ O
and -X- _ O
safety -X- _ O
of -X- _ O
the -X- _ O
Shi-cha -X- _ B-Intervention
capsule -X- _ I-Intervention
, -X- _ O
a -X- _ O
Chinese -X- _ O
herbal -X- _ O
formula -X- _ O
, -X- _ O
in -X- _ O
the -X- _ O
treatment -X- _ O
of -X- _ O
patients -X- _ B-Patient
with -X- _ I-Patient
wind-cold -X- _ I-Patient
type -X- _ I-Patient
common -X- _ I-Patient
cold. -X- _ I-Patient
In -X- _ O
our -X- _ O
multi-center -X- _ O
, -X- _ O
prospective -X- _ O
, -X- _ O
double-blind -X- _ O
, -X- _ O
randomized -X- _ O
, -X- _ O
placebo-controlled -X- _ O
, -X- _ O
dose-escalation -X- _ O
trial -X- _ O
, -X- _ O
patients -X- _ B-Patient
with -X- _ I-Patient
wind-cold -X- _ I-Patient
type -X- _ I-Patient
common -X- _ I-Patient
cold -X- _ I-Patient
received -X- _ O
0.6 -X- _ B-Intervention
g -X- _ I-Intervention
of -X- _ I-Intervention
Shi-cha -X- _ I-Intervention
capsule -X- _ I-Intervention
plus -X- _ I-Intervention
0.6 -X- _ I-Intervention
g -X- _ I-Intervention
placebo -X- _ I-Intervention
( -X- _ I-Intervention
group -X- _ I-Intervention
A -X- _ I-Intervention
) -X- _ I-Intervention
, -X- _ I-Intervention
1.2 -X- _ I-Intervention
g -X- _ I-Intervention
of -X- _ I-Intervention
Shi-cha -X- _ I-Intervention
capsule -X- _ I-Intervention
( -X- _ I-Intervention
group -X- _ I-Intervention
B -X- _ I-Intervention
) -X- _ I-Intervention
, -X- _ O
or -X- _ O
1.2 -X- _ B-Comparison
g -X- _ I-Comparison
placebo -X- _ I-Comparison
( -X- _ I-Comparison
group -X- _ I-Comparison
C -X- _ I-Comparison
) -X- _ I-Comparison
, -X- _ O
three -X- _ O
times -X- _ O
daily -X- _ O
for -X- _ O
3 -X- _ O
days -X- _ O
and -X- _ O
followed -X- _ O
up -X- _ O
to -X- _ O
10 -X- _ O
days. -X- _ O
The -X- _ O
primary -X- _ O
end -X- _ O
point -X- _ O
was -X- _ O
all -X- _ O
symptom -X- _ O
duration. -X- _ O
The -X- _ O
secondary -X- _ O
end -X- _ O
points -X- _ O
were -X- _ O
main -X- _ O
symptom -X- _ O
duration -X- _ O
, -X- _ O
minor -X- _ O
symptom -X- _ O
duration -X- _ O
, -X- _ O
the -X- _ O
changes -X- _ O
in -X- _ O
cumulative -X- _ O
symptom -X- _ O
score -X- _ O
, -X- _ O
main -X- _ O
symptom -X- _ O
score -X- _ O
, -X- _ O
and -X- _ O
minor -X- _ O
symptom -X- _ O
score -X- _ O
4 -X- _ O
days -X- _ O
after -X- _ O
the -X- _ O
treatment -X- _ O
, -X- _ O
as -X- _ O
well -X- _ O
as -X- _ O
adverse -X- _ O
events. -X- _ O
A -X- _ O
total -X- _ O
of -X- _ O
377 -X- _ O
patients -X- _ O
were -X- _ O
recruited -X- _ O
and -X- _ O
360 -X- _ B-Patient
met -X- _ O
the -X- _ O
inclusive -X- _ O
criteria -X- _ O
; -X- _ O
120 -X- _ O
patients -X- _ O
constituted -X- _ O
each -X- _ O
treatment -X- _ O
group. -X- _ O
Compared -X- _ B-Outcome
with -X- _ I-Outcome
patients -X- _ I-Outcome
in -X- _ I-Outcome
group -X- _ I-Outcome
C -X- _ I-Outcome
, -X- _ I-Outcome
patients -X- _ I-Outcome
in -X- _ I-Outcome
groups -X- _ I-Outcome
A -X- _ I-Outcome
and -X- _ I-Outcome
B -X- _ I-Outcome
had -X- _ I-Outcome
significant -X- _ I-Outcome
improvement -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
all -X- _ I-Outcome
symptom -X- _ I-Outcome
duration -X- _ I-Outcome
, -X- _ I-Outcome
main -X- _ I-Outcome
symptom -X- _ I-Outcome
duration -X- _ I-Outcome
, -X- _ I-Outcome
minor -X- _ I-Outcome
symptom -X- _ I-Outcome
duration -X- _ I-Outcome
, -X- _ I-Outcome
as -X- _ I-Outcome
well -X- _ I-Outcome
as -X- _ I-Outcome
change -X- _ I-Outcome
from -X- _ I-Outcome
baseline -X- _ I-Outcome
of -X- _ I-Outcome
cumulative -X- _ I-Outcome
symptom -X- _ I-Outcome
score -X- _ I-Outcome
, -X- _ I-Outcome
main -X- _ I-Outcome
symptom -X- _ I-Outcome
score -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
minor -X- _ I-Outcome
symptom -X- _ I-Outcome
score -X- _ I-Outcome
at -X- _ I-Outcome
day -X- _ I-Outcome
4. -X- _ I-Outcome
The -X- _ I-Outcome
symptom -X- _ I-Outcome
durations -X- _ I-Outcome
and -X- _ I-Outcome
scores -X- _ I-Outcome
showed -X- _ I-Outcome
slight -X- _ I-Outcome
superiority -X- _ I-Outcome
of -X- _ I-Outcome
group -X- _ I-Outcome
B -X- _ I-Outcome
over -X- _ I-Outcome
group -X- _ I-Outcome
A -X- _ I-Outcome
, -X- _ I-Outcome
although -X- _ I-Outcome
these -X- _ I-Outcome
differences -X- _ I-Outcome
were -X- _ I-Outcome
not -X- _ I-Outcome
statistically -X- _ I-Outcome
significant. -X- _ I-Outcome
There -X- _ I-Outcome
were -X- _ I-Outcome
no -X- _ I-Outcome
differences -X- _ I-Outcome
in -X- _ I-Outcome
adverse -X- _ I-Outcome
events. -X- _ I-Outcome
The -X- _ O
Shi- -X- _ B-Intervention
cha -X- _ I-Intervention
capsule -X- _ I-Intervention
is -X- _ O
efficacious -X- _ B-Outcome
and -X- _ I-Outcome
safe -X- _ I-Outcome
for -X- _ I-Outcome
the -X- _ I-Outcome
treatment -X- _ I-Outcome
of -X- _ O
patients -X- _ B-Patient
with -X- _ I-Patient
wind-cold -X- _ I-Patient
type -X- _ I-Patient
common -X- _ I-Patient
cold. -X- _ I-Patient
Larger -X- _ O
trials -X- _ O
are -X- _ O
required -X- _ O
to -X- _ O
fully -X- _ O
assess -X- _ O
the -X- _ O
benefits -X- _ O
and -X- _ O
safety -X- _ O
of -X- _ O
this -X- _ O
treatment -X- _ O
for -X- _ O
common -X- _ O
cold -X- _ O
. -X- _ O

